
Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Myeloproliferative neoplasm laboratory findings
Introduction
Overview
Overview
Laboratory findings associated with the diagnosis of myeloproliferative neoplasm include leukocytosis, thrombocytopenia, and anemia.
Laboratory Findings
Laboratory Findings
Laboratory findings associated with myeloproliferative neoplasm include:[1][2][3][4][5][6]
- Increased granulocytes of all types
- Increased basophils and eosinophils
- Thrombocytopenia or thrombocythemia
- Anemia or polycythemia
- Blood chemistry
- The following blood levels may be elevated:
- Blood urea nitrogen (BUN)
- Creatinine
- Phosphate
- Lactate dehydrogenase (LDH)
- Alanine aminotransferase (ALT)
- Aspartate transaminase (AST)
- Uric acid
- Bleeding and clotting factors
- The following blood parameters may be elevated:
- Prothrombin time (PT) or international normalized ratio (INR)
- Partial thromboplastin time (PTT)
- D-dimer
- Flow cytometry helps determine the type of cells that are present.
- Chromosome changes that may occur in some people with leukemia include:
- Translocations
- Inversions
- Loss or gain of a chromosome
- Similar to cytogenetics, but more specific for particular chromosomal translocations
- Polymerase chain reaction
- Helpful to detect specific abnormalities in blood or bone marrow cells. Abnormalities can be found even if very few leukemia cells are present in a tissue sample.
- Neutrophil alkaline phosphatase level
- Vitamin B12 (or B12 binding capacity) level
- Erythropoietin level
- Molecular testing for JAK2, CALR, and MPL mutations
Gallery
Gallery
-
Representative Philadelphia negative metaphase bone marrow cell with a t(9;12)(q34;p13) translocation. (a) G-banded karyotype; (b) FISH analysis demonstrates lack of BCR-ABL1 fusion but reveals a small third signal from the ABL1 probe (arrow) and; (c) The ETV6 split signal (arrowed in red) on der(9)t(9;12) from the break-apart FISH probe shows the gene rearrangement and confirms G banding results. The red/green fusion signal marks the normal gene.[7]
References
References
- ↑ Canadian Cancer Society.2015.http://www.cancer.ca/en/cancer-information/cancer-type/leukemia-chronic-myelogenous-cml/diagnosis/?region=ab
- ↑ James W. Vardiman (2009). “Chronic myelogenous leukemia, BCR-ABL1+”. American journal of clinical pathology. 132 (2): 250–260. doi:10.1309/AJCPUN89CXERVOVH. PMID 19605820. Unknown parameter
|month=ignored (help) - ↑ Sánchez-Muñoz, Laura; Alvarez-Twose, Ivan; GarcÃa-Montero, Andrés C; Teodosio, Cristina; Jara-Acevedo, MarÃa; Pedreira, Carlos E; Matito, Almudena; Morgado, Jose Mario T; Sánchez, Maria Luz; Mollejo, Manuela; Gonzalez-de-Olano, David; Orfao, Alberto; Escribano, Luis (2011). “Evaluation of the WHO criteria for the classification of patients with mastocytosis”. Modern Pathology. 24 (9): 1157–1168. doi:10.1038/modpathol.2011.84. ISSN 0893-3952.
- ↑ Levene, Malcolm I.; Lewis, S. M.; Bain, Barbara J.; Imelda Bates. Dacie & Lewis Practical Haematology. London: W B Saunders. p. 586. ISBN 0-443-06377-X.
- ↑ O’Brien, S. (2004). “Chronic Myelogenous Leukemia and Myeloproliferative Disease”. Hematology. 2004 (1): 146–162. doi:10.1182/asheducation-2004.1.146. ISSN 1520-4391.
- ↑ Murakami J, Shimizu Y (2013). “Hepatic manifestations in hematological disorders”. Int J Hepatol. 2013: 484903. doi:10.1155/2013/484903. PMC 3626309. PMID 23606974.
- ↑ Gancheva, Katya; Virchis, Andres; Howard-Reeves, Julie; Cross, Nick CP; Brazma, Diana; Grace, Colin; Kotzampaltiris, Paul; Partheniou, Fedra; Nacheva, Elisabeth (2013). “Myeloproliferative neoplasm with ETV6-ABL1 fusion: a case report and literature review”. Molecular Cytogenetics. 6 (1): 39. doi:10.1186/1755-8166-6-39. ISSN 1755-8166.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2] Shyam Patel [3]

![Representative Philadelphia negative metaphase bone marrow cell with a t(9;12)(q34;p13) translocation. (a) G-banded karyotype; (b) FISH analysis demonstrates lack of BCR-ABL1 fusion but reveals a small third signal from the ABL1 probe (arrow) and; (c) The ETV6 split signal (arrowed in red) on der(9)t(9;12) from the break-apart FISH probe shows the gene rearrangement and confirms G banding results. The red/green fusion signal marks the normal gene.[7]](https://www.wikidoc.org/images/b/ba/MPN-FISH.jpg)